China Medical System Holdings Limited
VC Fund
Shenzhen, China
China Medical System Holdings Limited is a VC fund in Shenzhen focused on Biotechnology and Medical. CMS is a specialty pharmaceutical company based in China, focusing on marketing, promotion and sales of prescription drugs and other medicinal products to all therapeutic departments in hospitals nation-wide. CMS builds up its product portfolio for its target markets by asset acquisition, equity investment, licensing-in and distribution partnershipon the global basis as well as in-house R&D.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries China Medical System Holdings Limited invests in
Stages China Medical System Holdings Limited invests in
Countries China Medical System Holdings Limited invests in
Investment Focus
Industry
- Biotechnology 5 (63%)
- Medical 3 (38%)
- Health Care 2 (25%)
- Pharmaceutical 2 (25%)
- Genetics 1 (13%)
Stage
- Seed 1 (13%)
- Series A 1 (13%)
- Series B 1 (13%)
- Funding Round 1 (13%)
- Corporate Round 1 (13%)
Country
- China 4 (50%)
- United Kingdom 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Beyond Therapeutics employs its ExCEED technology to speed the discovery and development of novel medications for unmet therapeutic needs. | $29.6M / Series A / Jul 30, 2026 | ||
| AccurEdit develops and commercializes safe and targeted in vivo gene editing and delivery technologies to treat severe hereditary and acquired diseases globally. The company has built a leading end-to-end platform specializing in RNA synthesis, gene editing, and delivery for in vivo gene editing therapies. | $75M / Series A / Aug 29, 2025 | ||
| Baiyiyuan Biotechnology is a biomedical material developer specializing in advanced biological tissue regeneration products. The company focuses on research, development, and production of new biomedical materials, particularly those used for tissue repair and wound healing | Corporate Round / May 09, 2025 | ||
| NeuroDawn Pharmaceutical develops new drugs that are designed to treat central nervous system diseases. | $28.1M / Series B / Jan 12, 2024 | ||
| Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs. | $13.7M / Seed / Oct 26, 2023 | ||
| Healsun Biopharm is a pharmaceutical company development processes such as molecular construction, stable cell line screening, cell culture process development, protein purification and process development, antibody-coupled drug process development and bioanalytical method development. | $27.8M / Series B / Oct 07, 2023 | ||
| N1 Life is an innovative biomedical company that focused on drug discovery and development of PDC drugs in the anti-tumor pipeline. | $10M / Seed / Apr 17, 2023 | ||
| Destiny Pharma is an innovative pharmaceutical company dedicated to the development of novel antimicrobial products.Our XF series of compounds have a mechanism of action that is fundamentally different from all existing antibiotics. As the likelihood of resistance developing is very remote, they offer potential advantages in controlling thedrug-resistant bacteria that are at the centre of a global healthcare crisis. | $8M / Sep 04, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does China Medical System Holdings Limited invest in?
China Medical System Holdings Limited invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did China Medical System Holdings Limited last invest?
The most recent investment recorded for China Medical System Holdings Limited closed in Jul 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
